

*26th JSSX Annual Meeting in Hiroshima
November 17, 2011*

EXPECTATIONS FOR THE NEXT- GENERATION JSSX

*President of JSSX
President of Kyoto Pharmaceutical University
Ken-ichi Inui*

Constitution of JSSX Members (Oct., 2011)

Academia	527
Companies	1001
Hospitals	114
Others	95
Students	362
Total	2119

Missions as the President of JSSX

For Strong Structure of JSSX (Academia, Pharmaceutical Companies, Hospitals and etc.), and Distinctive and Attractive Academic Society in the Field of Medicine and Pharmaceutical Sciences:

- 1. Activation and Enrichment in the JSSX Annual Meeting*
- 2. DMPK, More Attractive Journal for Authors and Readers*
- 3. Globalization of JSSX and the Partnership with ISSX*

Directors (2011)

President



Ken-ichi Inui, Prof., Ph.D.
Kyoto Pharmaceutical University

President-Elect



Hiroshi Suzuki, Prof., Ph.D.
The University of Tokyo Hospital



Takashi Igarashi, Ph.D.
Nippon Boehringer Ingelheim Co., Ltd.



Takashi Izumi, Ph.D.
Daiichi Sankyo Co., Ltd.



Teruko Imai, Prof., Ph.D.
Kumamoto University



Shigeru Ohta, Prof., Ph.D.
Hiroshima University



Toshiyuki Kume, Ph.D.
Mitsubishi Tanabe Pharma
Corporation Inc.



Hideyuki Saito, Prof., Ph.D.
Kumamoto University Hospital



Mikiyoshi Takano, Prof., Ph.D.
Hiroshima University



Ikumi Tamai, Prof., Ph.D.
Kanazawa University



Kan Chiba, Prof., Ph.D.
Chiba University



Takahiko Baba, Ph.D.
Shionogi & Co., Ltd.



Masakiyo Hosokawa, Prof., Ph.D.
Chiba Institute of Science



Toshiya Moriwaki, Ph.D.
Takeda Pharmaceutical Company



Hiroshi Yamazaki, Prof., Ph.D.
Showa Pharmaceutical University



Yamada Hideyuki, Prof., Ph.D.
Kyushu University



Tsuyoshi Yokoi, Prof., Ph.D.
Kanazawa University

Directors (2010)

President



Kenichi Inui, Prof., Ph.D.
Kyoto Pharmaceutical University

President-Elect



Hiroshi Suzuki, Prof., Ph.D.
The University of Tokyo Hospital



Takashi Igarashi, Ph.D.
Nippon Boehringer Ingelheim Co., Ltd.



Takashi Izumi, Ph.D.
Daiichi Sankyo Co., Ltd.



Teruko Imai, Prof., Ph.D.
Kumamoto University



Shigeru Ohta, Prof., Ph.D.
Hiroshima University



Hideyuki Saito, Prof., Ph.D.
Kumamoto University Hospital



Mikihisa Takano, Prof., Ph.D.
Hiroshima University



Ikumi Tamai, Prof., Ph.D.
Kanazawa University



Toshio Teramura, Ph.D.
Astellas Pharma Inc.



Takahiko Baba, Ph.D.
Shionogi & Co., Ltd.



Masahiro Hayashi, Prof., Ph.D.
Tokyo University of Pharmacy
and Life Sciences



Masakiyo Hosokawa, Prof., Ph.D.
Chiba Institute of Science



Toshiya Moriwaki, Ph.D.
Takeda Pharmaceutical Company



Hiroshi Yamazaki, Prof., Ph.D.
Showa Pharmaceutical University



Yamada Hideyuki, Prof., Ph.D.
Kyushu University



Tsuyoshi Yokoi, Prof., Ph.D.
Kanazawa University

Auditors



Toshio Suwa, Prof., Ph.D.
Keio University



Yoshinobu Yoshimura, Ph.D.
Takeda Analytical Research Laboratories

Secretariat

executive director



Sudo Kenichi, Ph.D.
DAIICHI SANKYO RD ASSOCIE CO.,LTD



Yoshimi Chiba



Hiromi Nishizawa

Editorial office

Editor in Chief,
DMPK



Ikumi Tamai, Prof., Ph.D.
Kanazawa University

Editor in Chief,
DMPKNewsLetter



Hiroaki Yuasa, Prof., Ph.D.
Nagoya City University



Maki Sakai

Committees

- ◆ General Affairs Committee (Mikihisa Takano)
- ◆ Finance Committee (Takahiko Baba)
- ◆ DMPK Editorial Committee (Ikumi Tamai)
- ◆ DMPK Support Committee (Teruko Imai)
- ◆ International Affairs Committee (Hiroshi Yamazaki)
- ◆ The Society Activation and Planning Committee (Hideyuki Saito)
- ◆ Future Perspective Committee (Hiroshi Suzuki)
- ◆ Forum Committee (Hideyuki Yamada)
- ◆ Newsletter Editorial Committee (Hiroaki Yuasa)

Globalization of Meeting

25th JSSX Annual Meeting in Tokyo (Oct., 2009)

Submitted Abstracts (289)

Domestic Abroad	280 9	Oral (108)	Poster (181)
Japan		103	177
Taiwan		2	1
Thailand		0	2
New Zealand		1	1
Indonesia		1	0
Germany		1	0

Total Attendees (1,116)

	Japanese (1,092)	Foreigner (24)
Member	591	5
Non-member	262	5
Graduate student	146	7
Under graduate	30	0
Invited	63	7

26th JSSX Annual Meeting in Hiroshima

Preregistered Attendees (753)

	Domestic (734)	Abroad (19)
Member	444	4
Non-member	135	4
Graduate Student	101	6
Under Graduate	26	0
Invited	28	5


Workshops and Short Courses of JSSX

Year	Themes	Attendees
2011	25th Workshop of JSSX “Stop the termination of new drug development due to toxicity -What can be done by pharmacokinetics researchers? -”	250
	5th Short Course “The Front Lines for Corporate Research on Induction and Metabolism using Cells.”	168
2010	24th Workshop of JSSX “The advantage of PPK-PD approaches for drug development.”	271
	4th Short Course “How to conduct ADME research for effectively producing new drugs at the drug discovery stage using biomarkers and the PK/PD approach. - Striving for improving the success rate of clinical POC acquisition. –”	137
2009	23rd Workshop of JSSX “A New Phase of ADME-TOX (Absorption, Distribution, Metabolism, Excretion and Toxicity) for Safe Drug Discovery.”	298
	3rd Short Course “Application of Transporter (Transmembrane) Study in New Drug Development.”	144


Drug Metabolism and Pharmacokinetics (DMPK), Official Journal of JSSX

1. New Editorial Committee from 2010 (Including Two Foreign Boards).
2. Grants-in-Aid for Scientific Research was Received from 2008 to 2011.
(3,400,000 – 4,400,000 yen)
3. Theme Issue was Published.
4. Impact Factor of 2010 was 2.558.
5. Increase of Submitted Manuscript.
6. Rejection Ratio is around 40%.

Impact Factors of Japanese Journals




Submitted Number of Manuscripts to DMPK (Inside and Outside Japan)




- Number of submission is increasing.
- Submission from outside of Japan is increasing.

Frequently Used Keywords of Articles in DMPK (2007-2010)



Perspectives in Drug Transporter Studies


Drug transporter research will much more contribute to the pharmacotherapy and drug-discovery/development. However, we need more effort for the patients' health care by establishment of "Personalized Medicine".



Questionnaire Survey for Pharmaceutical Company Employees

Planning & Survey: The Society Activation and Planning Committee

Expected Topics & Programs in JSSX Annual Meetings by Members



N=167

The Requests to JSSX from Pharmaceutical Companies

Contribution to Drug Discoveries and Developments

1. Information for administration and regulation
2. Prediction of clinical pharmacokinetics, pharmacodynamics or toxicokinetics
3. Micro-dosing study
4. Translational research

Drug Metab. Pharmacokinet. 26 (5): 441 (2011).

Editorial

The Challenge to Integrate Academic Research in Japan into Global R&D in Pharmaceutical Companies

Full text of this paper is available at <http://www.jstage.jst.go.jp/browse/dmpk>

The impact factor of *Drug Metabolism and Pharmacokinetics* (DMPK), the official journal of the Japanese Society for the Study of Xenobiotics (JSSX), has been increasing in recent years, reaching 2.544 in 2009 and 2.558 in 2010. This reflects increasing international interest in DMPK research in Japan and the availability of such work publicized in English.

In order to enhance this global appeal, JSSX has recently requested that all presentations at its annual meeting should be given in English, not in Japanese. This is important, as JSSX scientific meetings include both Japanese academics with access to unique technologies and international pharmaceutical industry researchers. The latter scientists have an important role to play as intermediaries between academics and senior management of pharmaceutical companies. In other words, the role of scientists in domestic and foreign company research institutes in Japan should be not only to conduct routine experimental studies for new drug application (NDA), but also to seek out innovative technology developed in Japan that could be usefully applied for new drug development.

I worked in the R&D institute in Japan of a foreign pharmaceutical company for 14 years, until 2010. One of my tasks then was to promote the development and adoption of novel Japanese technology by introducing Japanese professors to foreign colleagues based at headquarters and coordinating collaboration among Japanese academic scientists via our Japanese institute. International academic conferences, such as the JSSX, ISSX and MDO conferences, have provided great opportunities to introduce unique Japanese technology to foreign researchers and staff based at corporate headquarters. Although the needs of each company are different, depending on their development strategy, there have been many examples of successful technology transfer. In my own case, the company I worked for was very interested in Japanese academic research on drug transporters and biomarkers because of their potential usefulness in the drug development process.


Our Japanese R&D institute was able to establish novel in-house tools introduced from several Japanese universities, and we utilized them to profile the transporter substrate profiles of various drug candidates under development. Another example has been cooperation with Japanese academia in the field of quantitative protein analysis by LC-MS/MS. Technology to quantify proteins using mass spectrometry is of great value for drug development, including high-throughput screening. This technology also has potential in the field of biomarker analysis, including identification of novel peptide or protein markers with diagnostic or therapeutic potential. The goal of these collaborations was to establish the technology in-house at company drug development sites.

Unfortunately, the number of pharmaceutical company research institutes located in Japan has recently been decreasing owing to changes in global development strategies. Global harmonization of the Common Technical Document (CTD) has accelerated both the transfer of research centers in Japan to other less expensive Asian countries and the centralization of R & D at large central research centers. I believe that this trend may be counteracted by supporting early collaboration with researchers of companies with headquarters based outside of Japan to introduce cutting-edge technology in various disciplines through cooperation and open discussions at the personal level. The fact that Japanese scientific attainment in the field of DMPK is world-leading provides a unique opportunity for company scientists in Japan, in particular young scientists, not only at research institutes, but also those working in R&D, to capitalize on the work of academics in Japan. They have the opportunity to introduce novel techniques into the global R&D development process, thereby demonstrating the unique advantages of Japanese institutes and R&D functions to companies outside of Japan.

Takashi Igarashi, Ph.D.
JSSX Director (2010-2011)

Questionnaire Survey for Hospital Pharmacists

Expected Themes & Programs Regarding Drug Metabolism and Pharmacokinetics



The Requests to JSSX from Hospital Pharmacists

For Optimum Pharmacotherapy


-based on the knowledge of drug metabolism and pharmacokinetics-

1. Knowledges about drug metabolism and disposition
2. Technical skills for PK/PD approaches
3. Pharmacokinetics profiles of antibiotics, antineoplastic drugs, newly developed drugs
4. Skill for TDM, dosage regimen and personalized medicine

Adaptation for Reform of The Pharmacy Programs


4 years + 2 years + 3 years

Education for “Investigators of drug discovery and development”



6 years + 4 years


Education for the “Pharmacist-Scientists”



- Admission of undergraduate students to JSSX

EXPECTATIONS FOR THE NEXT-GENERATION JSSX

- 1. Noteworthy Research Outcomes Influential to World Wide*
- 2. Prominent Position as Academic Society in Drug Discovery and Development*
- 3. Application of Basic Research Outcomes to Clinical Pharmacotherapy*
- 4. Encouragement for Young Scientists and Pharmacist-Scientists*
- 5. More Globalization and Tight Partnership with ISSX*



Hiroshi Suzuki, Prof., Ph.D.
The University of Tokyo Hospital

Join the Japanese Society for the Study of Xenobiotics (JSSX) and the International Society for the Study of Xenobiotics (ISSX) at a joint scientific meeting October 12 – 17, 2014 in San Francisco, California, USA.



Meeting Organizing Committee

Tetsuya Terasaki, PhD (*Meeting Co-Chair*)
Tohoku University

Eric Johnson, PhD (*Meeting Co-Chair*)
The Scripps Research Institute

Toshio Teramura, PhD
Astellas Pharma, Inc.

Kan Chiba, PhD
Chiba University

Natlie Hosea
Pfizer Inc.

Takashi Izumi, PhD
Daiichi Sankyo Co., Ltd.

Mikihisa Takano, PhD
Hiroshima University

Ikumi Tamai, PhD
Kanazawa University

Bill Smith, PhD
Pfizer Inc.

Frank Gonzalez, PhD
National Cancer Institute

Scott Obach, PhD
Pfizer Inc.

Hiroshi Yamazaki, PhD
Showa Pharmaceutical University

Hiroshi Suzuki, PhD
The University of Tokyo University

Paul Ortiz de Montellano, PhD
University of California, San Francisco

Xiao-bo Zhong
University of Kansas Medical Center

Features of this Meeting

This meeting will feature short courses, keynote lectures delivered by leading researchers, parallel sessions, poster sessions, awards presentations, a vendor exhibition, and multiple opportunities for attendees to enjoy social interaction with friends, acquaintances, and other meeting attendees.

Meeting Venue

With its prime location near Nob Hill and Chinatown, the Hilton San Francisco Union Square provides easy access to all that San Francisco has to offer.

San Francisco is renowned for its steep rolling hills, eclectic architecture, and famous landmarks including the Golden Gate Bridge, cable cars, Lombard Street, Alcatraz and much more.

Its international airport is a major gateway to Asia with direct flights from more than 40 countries daily.



Save the Dates and Make Plans to join us in San Francisco October 12 – 17, 2014



Joint Scientific Meeting of JSSX and ISSX

Meeting Co-chairs

Tetsuya Terasaki, PhD — JSSX

Tohoku University

Eric Johnson, PhD — ISSX

The Scripps Research Institute

October 12 – 17, 2014 in
San Francisco, California, USA.